Article
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Lancet (London, England) - 4 Feb 2023
Swen Jesse J, van der Wouden Cathelijne H, Manson Lisanne En, Abdullah-Koolmees Heshu, Blagec Kathrin, Blagus Tanja, Böhringer Stefan, Cambon-Thomsen Anne, Cecchin Erika, Cheung Ka-Chun, Deneer Vera Hm, Dupui Mathilde, Ingelman-Sundberg Magnus, Jonsson Siv, Joefield-Roka Candace, Just Katja S, Karlsson Mats O, Konta Lidija, Koopmann Rudolf, Kriek Marjolein, Lehr Thorsten, Mitropoulou Christina, Rial-Sebbag Emmanuelle, Rollinson Victoria, Roncato Rossana, Samwald Matthias, Schaeffeler Elke, Skokou Maria, Schwab Matthias, Steinberger Daniela, Stingl Julia C, Tremmel Roman, Turner Richard M, van Rhenen Mandy H, Dávila Fajardo Cristina L, Dolžan Vita, Patrinos George P, Pirmohamed Munir, Sunder-Plassmann Gere, Toffoli Giuseppe, Guchelaar Henk-Jan
Abstract excerpt
BACKGROUND: The benefit of pharmacogenetic testing before starting drug therapy has been well documented for several single gene-drug combinations. However, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetic panel has not been rigorously assessed. METHODS: We conducted an open-label, multicentre, controlled, cluster-randomised, crossover implementation study of a 12-gene...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.